|
|
Support : Dialog Search Aids
: Pharmaprojects Therapeutic Class Codes
Pharmaprojects Therapeutic Class Codes
(DIALOG Files 128*, 928*)
*(Subscriber access.)
 View the PDF version of this document
This list includes the therapeutic categories
in order of their codes. This allows you to
see the hierarchy involved in the classification.
top
| A |
ALIMENTARY/METABOLIC PRODUCTS |
| A1A |
STOMATOLOGICAL
Products for use in the anterior part of the mouth ie. periodontium (teeth), gingivae (gums), tongue, palate etc, but not the throat. It includes treatments for gingivitis (inflammation of the gums), pyorrhea (periodontitis) and oral ulcers. Compounds in development include antibacterial formulations, inhibitors of the immune system, and bone morphogenetic protein-2 and osteogenic protein. |
| A2A |
ANTACID/ANTIFLATULENT
Generally simple basic compounds that neutralize excess acidity in the stomach for the treatment of indigestion (dyspepsia). Combinations of the antacids aluminium and magnesium are in development. |
| A2B |
ANTIULCER
Products for the treatment of duodenal, gastric, peptic ulcers and ulcers caused by Zollinger-Ellison syndrome. Includes prostaglandins, H2-antagonists, proton pump (H+/K+-ATPase inhibitors) and phosphodiesterase inhibitors. |
| A3 |
ANTISPASMODIC
Products for the treatment of symptomatic diffuse oesophageal spasm, which may cause chest pain (oesophagitis reflux, heartburn) and gastro-oesophageal reflux. Drugs undergoing investigation include selective antimuscarinic agents and atypical b 3-agonists. |
| A4A |
ANTIEMETIC
Products for emesis, nausea and vomiting, including improved 5-HT3 antagonists, cannabinoids, selective vasopressin V1 receptor antagonists, as well as dopamine D2, tachykinin and 5-HT4 antagonists. |
| A4B |
GASTROPROKINETIC
Products for delayed emptying of the contents of the stomach due to gastric hypomotility, which can lead to several gastrointestinal disorders, and compounds for pancreatic and biliary dyskinesias. Drug strategies include dopamine antagonistic activity, the indirect enhancement of acetylcholine release, k opioid agonists and 5-HT4 agonists. Cholecystokinin (CCK) antagonists for biliary dyskinesias. |
| A5B |
HEPATOPROTECTIVE
Products for jaundice (hyperbilirubinaemia), liver cirrhosis, liver fibrosis and hepatic (portal-systemic) encephalopathy. Also includes products that protect against the degradation of liver tissues by by-products of detoxification and liver metabolism and by other liver-damaging diseases. Enzyme inducers of bilirubin oxidase, immunosuppressants and inhibitors of hydroxylases and transaminases are being investigated. Also includes compounds for the treatment of hepatic dysfunction and hepatic insufficiency. |
| A5D |
GALLSTONE THERAPY
Products for use in gallstones (biliary calculi) therapy include bile salt re-uptake inhibitors. |
| A6 |
LAXATIVE
Laxatives promote defaecation and are indicated for the treatment of constipation. Formulations of existing laxatives, and opioid antagonists are being investigated. |
| A7 |
ANTIDIARRHOEAL
Products in development for diarrhoea - the excessive faecal loss of fluid and electrolytes - include specific opioid agonists (both m and d receptors), enkephalinase inhibitors, somatostatin analogues and chelating agents. |
| A8A3 |
ANORECTIC/ANTIOBESITY
Most anorectics suppress appetite via an effect on the central nervous system. They affect the dopamine, opioid, norepinephrine and 5-HT-mediated pathways of appetite control. Products under investigation include 5-HT reuptake inhibitors, cholecystokinin agonists, as well as b 3-adrenoceptor agonists which stimulate thermogenesis and also b 3-adrenoceptor antagonists which suppress endogenous glucose production. |
| A9 |
DIGESTIVE
Digestants promote the process of digestion in the gastrointestinal tract where there is a lack of one or more specific substances that are involved in the digestion of food, including formulations of pancreatin with high lipase content. |
| A10B |
ANTIDIABETIC
Products for the treatment of diabetes mellitus include recombinant human insulin, encapsulated insulin-producing cells, and hypoglycaemic agents, such as a 2-adrenoceptor antagonists, somatomedins (somatomedin-C, insulin-like growth factor-1; somatomedin-A, IGF-2) and a -glucosidase inhibitors. |
| A10C |
SYMPTOMATIC ANTIDIABETIC
Products for the treatment of secondary complications of diabetes, such as glycosuria, polydypsia, ketosis, microangiopathy, nephropathy, retinopathy and neuropathy include aldose reductase inhibitors glycosylation inhibitors, ciliary neurotrophic factors and regeneration of nerve cells. |
| A11A |
NUTRITIONAL SUPPLEMENT
Mineral supplements, preparations of amino acids or trace elements, parenteral nutrition preparations and vitamin preparations for a variety of conditions are being developed. |
| A14 |
ANABOLIC
Anabolics are primarily of use in the rapid recovery from cachexia and protein-wasting disorders. Products include those which reduce plasma tumour necrosis factor levels. |
| A15 |
APPETITE STIMULANT
Products which stimulate appetite are of use in anorexia (loss of appetite, not the mental disorder, anorexia nervosa (see Antineurosis (N5D)). Compounds in development include inhibitors of gastrin release, cannabinoids, and cholecystokinin (CCK) antagonists. |
| A16 |
INFLAMMATORY AND BOWEL DISORDERS
Includes compounds for the treatment of colitis, ulcerative colitis, Crohn's disease, inflammatory bowel disease, irritable bowel syndrome, pancreatitis, gastritis, gasteroenteritis, gastroparesis, GI motility dysfunction and short bowel syndrome. |
| A17 |
METABOLIC AND ENZYME DISORDERS
Includes products for the treatment of Coeliac disease, Fabry's disease, Gaucher's disease, homocystinuria, hyperammonaemia, hyperbilirubinaemia, hyperkalaemia, hyperoxaluria, hyperphosphataemia, hyperprolactinaemia, hyponatraemia, acidosis, cystinosis, Pompe's disease, Tay-Sachs disease, sucrase isomaltase deficiency and Wilson's disease. |
| A18Z |
ALIMENTARY/METABOLIC GENERAL
Anything that cannot be placed in any of the other alimentary categories. Includes choleretics which stimulate the secretion of bile. |
top
| B |
BLOOD AND CLOTTING PRODUCTS |
| B1A |
ANTICOAGULANT
Products being developed that prevent the formation of blood clots include inhibitors of Factor VIIa and Factor Xa, a 1-antitrypsins, low molecular weight heparins, and recombinant versions of hirudin. |
| B1B1 |
FIBRINOLYTIC
Fibrinolysis is the process by which blood clots are dissolved in the body. Products that are being developed include anistreplase, recombinant versions of urokinase and pro-urokinase (PUK), and second-generation tPA products (tPA-2). |
| B1B9 |
ANTITHROMBOTIC
An antithrombotic prevents the aggregation of platelets (thrombocytes). Thrombin inhibitors in development include purified forms of the fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) and recombinant versions of antithrombin III. Inhibitors of platelet aggregation include calcium antagonists, PAF-antagonists, prostaglandin (PG) derivatives and glycoprotein (GPIIb/IIIa) antagonists. |
| B2A |
ANTIFIBRINOLYTIC
Antifibrinolytics are used to treat disorders resulting from overactivity of the fibrinolytic system and in cases of haemorrhage resulting from hyperfibrinolysis. Recombinant plasminogen activator inhibitor-1 (rPAI-1) is being investigated. |
| B2B |
HAEMOSTATIC
Haemostatic compounds speed up the time it takes for bleeding to stop. Purified and recombinant versions of Factor VIII and Factor IX are being developed as are Factor VIII fragments, Factor VIIa, Factor XIIa and Tissue Factor. Other haemostatics in development include recombinant kallikrein antagonists and human polymorphonuclear (PMN) elastase inhibitors. |
| B3C1 |
ANTISICKLING
Products in development for sickle cell anaemia include stabilizers of the oxy-conformation of haemoglobin as well as polyethylene glycol (PEG)-conjugated forms of haemoglobin. |
| B3C9 |
ANTIANAEMIC
Products for the treatment or prevention of anaemia (such as iron-deficiency anaemia, aplastic (hypoplastic) anaemia, pernicious anaemia and thalassaemia) include iron formulations, interleukins-3, 4 and 6, granulocyte macrophage colony stimulating factor, cAMP phosphodiesterase inhibitors and formulations of vitamin B12. |
| B5A1 |
PLASMA SUBSTITUTE
New developments for plasma substitutes are focusing on suitable oxygen-carrying fluids and include perfluro chemicals and inulin (polyfructan) combined with haemoglobin. |
| B5A2 |
BLOOD FRACTION
Various blood clotting factors are under investigation for the treatment of haemophilias and other diseases. |
| B6A |
SEPTIC SHOCK TREATMENT
Products under investigation for systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock and sepsis-induced hypotension include tumour necrosis factor (TNF) and interleukin-1 (IL-1) inhibitors, various monoclonal antibodies fragments of Bactericidal Permeability Increasing (BPI) protein and nitric oxide inhibitors. |
| B7Z |
HAEMATOLOGICAL
This section includes products with a haematological action which is either unknown to Pharmaprojects, or is not specified by any of the other "B" categories. Products for the treatment of thrombocytopenia. Products being investigated include interleukin-6 (B-cell stimulating factor-2), and fusion molecules of granulocyte macrophage colony stimulating factor (GM-CSF) with interleukin-3. |
Last modified on 24 Feb 2012.
top
|
Related Search Aid:
Pharmaprojects (DIALOG Files 128, 928) Major Events in the Update Information (UP) Field
|
Dialog1
Support Home